Rilutek (riluzole), the first drug approved for amyotrophic lateral sclerosis

December 2000

Aventis is now marketing Rilutek (riluzole), the first drug approved for amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease).

ALS is a progressive, degenerative nerve disease...leading to muscle weakness, paralysis, and eventually death.

ALS is thought to be caused by excess glutamate, the primary excitatory neurotransmitter. Too much glutamate damages the nerves.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

fibromyalgia
Diabetes new warning that consumers shouldn't use any products containing phenylpropanolamine
Diabetes more focus on lowering POSTPRANDIAL glucose
Diabetes glyburide is useful for treating gestational diabetes
NSAIDs a new NSAID for osteoarthritis and rheumatoid arthritis called Mobicox (meloxicam).
Women's Health new SINGLE-tablet estrogen and progestin product called Premplus
Women's Health using testosterone for women
Women's Health Menopause Educator Certificate
Tamiflu or Relenza to PREVENT flu
Cardiology eating certain high potassium foods to reduce the risk of high high blood pressure and stroke.
Cardiology guidelines for potassium replacement
Cardiology more efforts to reduce the risk of heart attack and stroke in patients with intermittent claudication
Lupus DHEA (dehydroepiandrosterone) is useful for treating lupus
Neurology & Pain Rilutek (riluzole), the first drug approved for amyotrophic lateral sclerosis
Neurology & Pain multiple sclerosis patients using Novantrone
Dispensing centralized facilities and more unit-of-use packaging